http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2015018040-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78a80a8ab31cfe89047694762b8b0138
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
filingDate 2014-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6a18c930b4f0723eae7f2fcc60ecc73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec4eaf287c8f107a90d0a939420b53d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deec6a759c6c8abc1090815e196bb8ce
publicationDate 2016-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MX-2015018040-A
titleOfInvention THERAPEUTIC AGENTS FOR USE IN PROFILAXIS AND / OR TREATMENT OF HYPERCINETIC MOVEMENT DISORDERS.
abstract The present invention relates to the use of (RS) - [2- (3,4-dimethoxife nyl) ethyl] [2-hydroxy-3- (3-methylphenoxy) propyl] amine having the formula (IA) or a salt pharmaceutically acceptable thereof for the formulation of a pharmaceutical composition, useful for the prophylaxis and / or treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Touret's syndrome, restless legs syndrome, and tardive dyskinesia.
priorityDate 2013-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2372
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491994

Total number of triples: 36.